Viyash Scientific

Viyash Scientific FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Viyash Scientific (VIYASH.NS) as of Nov 4, 2026 is 196.07 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 14.00 % — a change of 1,300.96% (higher).

FCF Conversion

196.07 %

YoY

1,300.96%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Viyash Scientific is 2025 196.07 % . FCF Conversion Rate (FCF/EBITDA) of Viyash Scientific was 2024 14.00 % . It decreases by 1,300.96% higher compared to the previous year.

The Viyash Scientific FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-0.42 INR
Jan 1, 2019
185.98 INR
Jan 1, 2020
106.74 INR
Jan 1, 2021
64.91 INR
Jan 1, 2022
-0.98 INR
Jan 1, 2023
57.26 INR
Jan 1, 2024
14.00 INR
Jan 1, 2025
196.07 INR
The Viyash Scientific FCF Conversion history
YEARFCF ConversionYoY
196.07 %+1,300.96%
14.00 %-75.56%
57.26 %-5,968.76%
-0.98 %-101.50%
64.91 %-39.19%
106.74 %-42.61%
185.98 %-44,149.00%
-0.42 %-100.07%
622.68 %+75.63%
354.54 %-66.86%
1,069.91 %+806.56%
118.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viyash Scientific Stock analysis

What does Viyash Scientific do? Viyash Scientific Ltd generates revenue through the manufacturing and sale of veterinary pharmaceuticals and specialty chemicals. The company offers finished dose formulations, active pharmaceutical ingredients (APIs), and analytical services to clients in the pharmaceutical, personal care, and nutraceutical industries. Its products target therapies such as anthelmintics, anti-protozoals, nutraceuticals, NSAIDs, anti-infectives, and dermatology solutions. The firm operates primarily through its pharmaceuticals segment, with subsidiaries Alivira Animal Health Limited and SeQuent Research Limited supporting its analytical and bioanalytical service offerings. The company's analytical services include method validation, stability testing, microbiology, and in-house method development, adhering to pharmacopoeia monographs and customer-specific requirements. These services are provided to API, pharmaceutical, personal care, and nutraceutical companies seeking regulatory compliance and quality assurance. The firm's focus on targeted therapies and specialized services positions it to serve a niche market within the animal health sector. Viyash Scientific Ltd's revenue streams are derived from both product sales and service contracts. The pharmaceuticals segment, which includes APIs and finished formulations, represents a core business area, while analytical services form a complementary revenue source. The company leverages its subsidiaries to enhance its service capabilities, particularly in analytical and bioanalytical support for clients across multiple industries. Viyash Scientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viyash Scientific stock

FCF Conversion Rate (FCF/EBITDA) of Viyash Scientific is 196.07 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Viyash Scientific changed from 14.00 % to 196.07 %, representing a 1,300.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Viyash Scientific since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Viyash Scientific with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Viyash Scientific

All Key Metrics — Viyash Scientific